Shots:
- Labcorp has launched the Elecsys pTau-181 test to measure phosphorylated Tau 181 protein to help rule out Alzheimer’s-related amyloid pathology in individuals (≥55yrs.)
- The test delivers a 97.9% negative predictive value to help rule out Alzheimer’s pathology in symptomatic pts & offers a less invasive, more accessible alternative to brain scans or lumbar punctures
- Elecsys pTau217 is a diagnostic test, developed by Roche & cleared by the US FDA in 2025, that quantifies Phospho-Tau in plasma to help identify amyloid pathology
Ref: PRnewswire | Image: Labcorp |Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
